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Abstract
Introduction: Rheumatoid arthritis (RA) is an inflammatory disease of the joint characterized by chronic synovitis
causing pain, swelling and loss of function due to destruction of cartilage and bone. The complex series of
pathological events occurring in RA is largely regulated via excessive production of pro-inflammatory cytokines, the
most prominent being tumor necrosis factor (TNF). The objective of this work was to elucidate possible involvement
of group IVA cytosolic phospholipase A2 (cPLA2α) in TNF-induced regulation of synovitis and joint destructive
effectors in RA, to evaluate the potential of cPLA2α as a future therapeutic target.
Methods: The involvement of cPLA2α in tumor necrosis factor (TNF)-induced intracellular signaling cascades in
synoviocytes (synovial fibroblast-like cells) was analyzed by arachidonic acid (AA) release assay, synoviocyte
enzyme activity assay, gene expression analysis by real-time PCR and ELISA immunoassay for the detection of
prostaglandin E2 (PGE2), interleukin 8 (IL8) and stromelysin-1 (MMP3), respectively.
Results: Inhibitors of cPLA2α enzyme activity (AVX002, ATK) significantly reduced TNF-induced cellular release of
AA, PGE2, IL8 and MMP3. This reduction was evident both at transcriptional, protein or metabolite levels.
Interestingly, cPLA2α inhibition affected several key points of the arachidonyl cascade; AA-release,
cyclooxygenase-2 (COX2) expression and PGE2 production. Furthermore, the results suggest that cPLA2α is subject
to transcriptional auto-regulation as inhibition of cPLA2α resulted in reduced PLA2G4A gene expression in TNF-
stimulated synoviocytes.
Conclusions: cPLA2α appears to be an important regulator of central effectors of inflammation and joint destruction,
namely MMP3, IL8, COX2, and PGE2. Decreased transcription of the PLA2G4A and COX2 genes in response to
cPLA2α enzyme inhibition further suggest a self-reinforcing effect of cPLA2α inhibition in response to TNF.
Collectively, these results support that cPLA2α is an attractive therapeutic target candidate as its inhibition reduces
the production of multiple key pro-inflammatory factors involved in RA pathogenesis.
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Introduction
Rheumatoid arthritis (RA) is an auto-immune and systemic
inflammatory disease affecting 0.5-1% of the population,
worldwide. In RA, chronic synovitis causes pain, swelling and
loss of joint function due to degradation of cartilage and bone
erosion [1]. Activated fibroblast-like synoviocytes (FLS) in the
inflamed synovium are important contributors to arthritis
through supranormal production of prostanoids, cytokines,
chemokines, matrix degrading enzymes, angiogenic factors
and adhesion molecules, thus perpetuating inflammation and
joint destruction [2]. A key mechanism in the destructive
signaling loop of RA is a dysregulation of the level of the pro-
inflammatory cytokine tumor necrosis factor (TNF) [3,4]. TNF is
overexpressed in RA synovium where it elicits a variety of
biological effects on inflammation and immunity including
modulation of gene expression and inflammatory joint
destruction [5].
Phospholipase A2 (PLA2) enzymes release unsaturated fatty
acids such as arachidonic acid (AA) by hydrolysis of the sn-2
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ester bond of membrane glycerophospholipids. The
arachidonyl specific group IVA cytosolic PLA2 enzyme
(cPLA2α) encoded by the PLA2G4A gene is a major
contributor to the elevated levels of AA in inflammation [6,7].
cPLA2α activity is regulated at many levels; by increased
intracellular Ca2+ levels in response to pro-inflammatory stimuli,
by binding to lipid second messengers, by phosphorylation
induced by kinases, and by de novo gene transcription [8–10].
Following cPLA2α activation, the released AA is enzymatically
metabolized to bioactive eicosanoids including prostaglandins,
thromboxanes, lipoxins and leukotrienes [11]. Prostaglandin E2
(PGE2) is synthesized from AA through the cyclooxygenase
(COX) pathway and is generally recognized as a potent lipid
regulator of active inflammation [12]. The beneficial anti-
inflammatory effect of reducing PGE2 synthesis is well
recognized, and as such, non-steroidal anti-inflammatory drugs
(NSAIDS) targeting the COX enzymes are widely used for
symptomatic relief in RA [13]. However, long term use of
NSAIDS has adverse effects e.g. affecting the gastrointestinal-
and cardiovascular system and bone homeostasis [14–16]. The
development of TNF-blocking agents has revolutionized the
treatment of RA-patients and TNF-blockers are frequently used
in RA therapy. However, approximately one-third of patients do
not respond successfully to treatment [17]. Anti-TNF therapies
are also under scrutiny following reports of malignancies,
serious infections and long-term safety concerns [18,19].
Therefore, a search for alternative therapeutic targets is of
great interest.
Several lines of evidence point to a role for cPLA2α in
arthritis and inflammation, although the exact mechanisms of
how cPLA2α regulates disease activity is not fully elucidated
[7,20–23]. The aim of this study was to investigate the
involvement of cPLA2α in joint and bone-destructive signaling
in human synoviocytes. We identified cPLA2α as a regulator of
TNF-induced expression of key players in RA pathology
involved in bone and cartilage destruction, angiogenesis and
neutrophil recruitment, namely stromelysin-1 (matrix
metalloproteinase 3, MMP3), interleukin 8 (IL8), COX2 and
PGE2. Furthermore, our results suggest that cPLA2α is subject
to auto-regulation as inhibition of cPLA2α activity leads to
reduced expression of PLA2G4A mRNA in response to TNF.
Hence, our results support the comprehension that cPLA2α
may be a major contributor to synovitis and joint destruction in
RA, and therefore a potent therapeutic target candidate.
Materials and Methods
Reagents
Recombinant human TNF was from R&D systems
(Abingdon, UK). Arachidonyl trifluoromethyl ketone (AACOCF3,
ATK) was from Enzo Life Sciences (Farmingdale, NY, USA).
PBS was from Oxoid (Basingstoke, Hampshire, UK). [3H]-
arachidonic acid ([3H]-AA), and liquid scintillation cocktail
Ultima Gold were from NEN Perkin Elmer (St. Louis, MO,
USA). Leupeptin and pepstatin were from Roche Molecular
Biochemicals (Indianapolis, USA). M-MLV reverse
transcriptase, dNTPs and DTT were from Invitrogen (St. Louis,
MO, USA). Random hexamer primers and RNAsin were from
Promega (Madison, WI, USA). DNAse- and RNAse-free water
was from VWR (Pennsylvania, USA). RNeasy® minikit was
from Qiagen (Valencia, CA, USA), ELISA kits for PGE2, IL8
and MMP3 were from Cayman Chemicals (Ann Arbor, MI,
USA), Bender Medsystems (Vienna, Austria) and RayBiotech
(Norcross, GA, USA), respectively. AVX002 was provided by
Avexxin AS (Trondheim, Norway) and synthesized by
Synthetica AS (Oslo, Norway). All other reagents were from
Sigma-Aldrich (St. Louis, MO, USA).
Cell Culture
The human synovial sarcoma derived cell line SW982 was
purchased from ATCC (London, UK). The cells were
maintained in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% FBS, 0.1 mg/mL gentamicin and 0.3
mg/mL L-glutamine at 37°C with 10% CO2. Experiments were
performed at 3 days post-confluence following overnight serum
deprivation in serum-free DMEM. When inhibitors were applied,
cells were pretreated for 2 hrs before stimulation with TNF (10
ng/mL).
[3H]-arachidonic acid release assay
Cells were labeled for 18 hrs with [3H]-AA (0.4 μCi/mL) in
serum-free DMEM before experimental treatment. [3H]-AA
release was analyzed in triplicates as previously described
[24]. The results shown are released [3H]-AA in supernatants
relative to total [3H]-AA incorporated into the cells. IC50 values
for inhibitors were calculated as mean ± SD of at least 3
independent experiments.
Assay of cellular cPLA2α enzyme activity
SW982 synoviocytes were serum starved over-night before
stimulation with TNF (10 ng/mL, 6 hours). Cells were lysed and
200 μg of total protein was analyzed for cPLA2α activity as
described [24–27]. Bromoenol lactone (25 μM) and
dithiothreitol (2.36 mM) were included in all reactions to inhibit
activity of iPLA2 and sPLA2 [27].
Real-time reverse-transcription polymerase chain
reaction (RT2-PCR)
Total RNA was isolated using RNeasy® minikit (Qiagen)
according to kit protocol. RNA concentrations and integrity was
monitored by NanoDrop spectrophotometric measurement
(NanoDrop Technologies Inc. Wilmington DE, USA) and total
RNA (1 µg) was reverse transcribed as described in [24].
Specific primers for IL8, MMP3, COX2, PLA2G4A and GAPDH
with the following sense and antisense primers, were used in
standard real-time RT-PCRs, with SYBR Green as
fluorescence reporter: IL8, 5´-
GACATACTCCAAACCTTTCCAC-3´ and 3´-
CTTCTCCACAACCCTCTGC-5´, MMP3, 5´-
TGATGAACAATGGACAAAGGATAC -3´ and 3´-
CTGTGAGTGAGTGATAGAGTGG-5´, COX2, 5´-
GGGGATCAGGGATGAACTTT -3´ and 3´-
TGGCTACAAAAGCTGGGAAG -5´, PLA2G4A, 5´-
CATGCCCAGACCTACGATTT -3´ and 3´-
CCCAATATGGCTACCACAGG -5´, GAPDH, 5´-
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CATCAAGAAGGTGGTGAAGCAG-3´ and 3´-
TGTAGCCAAATTCGTTGTCATACC-5´. Cq values for each
amplification curve were calculated by the Mx3000P software
(Stratagene). Fold changes in mRNA expression and statistical
analysis were calculated by the REST 2009 software [28] with
mean PCR reaction efficiencies calculated by the LinRegPCR
software [29] using GAPDH as reference gene.
Enzyme-linked immunosorbent assay (ELISA)
ELISA analyses were performed according to their
respective kit protocols. The read-out for all ELISAs was
carried out with a Multiscan plate reader (Ascent Labsystems).
The corresponding Ascent software for Multiscan, Version
2.4.1 was used to obtain the data. Mean estimated IC50 value
for PGE2 production was calculated from 3 independent
experiments.
Statistical analysis
For AA release and ELISA analysis, statistical analyses were
performed in SPSS Statistics 20 using one-way ANOVA at
95% confidence level in conjunction with Tukey HSD test. For
real-time PCR data, statistical analysis was performed by the
REST 2009 software [28]. Differences were considered
significant at p ≤ 0.05.
Results
TNF is a potent inducer of joint destructive regulators
in synoviocytes
MMP3, IL8 and PGE2 are important regulators of
inflammation and joint destruction in RA [12,30,31]. Matrix
metalloproteinases (MMPs) are main contributors to RA
cartilage destruction and the levels of several MMP subgroups,
including MMP3, are elevated in RA synovial fluid [30,32]. The
chemokine IL8 is overexpressed in RA synovium and acts as
an angiogenic factor and chemoattractant for neutrophils
thereby maintaining persistent migration of inflammatory cells
into the synovium [31,33], while PGE2 is a powerful inducer of
inflammation [12]. As TNF is known to induce both IL8 and
MMP3 [3,34], we first characterized basal and TNF-induced
gene expression by real-time PCR and protein by ELISA to
justify the use of SW982 synoviocytes as a model for studying
the TNF response. Indeed, TNF increased mRNA expression
of MMP3 and IL8 by 45.6 ± 2.1-fold (p ≤ 0.01), and 18.1 ± 3.7-
fold (p ≤ 0.01), respectively (Figure 1A and B).
Correspondingly, TNF-induced protein expression was
observed as indicated by a twofold increase in MMP3 levels
from 5.5 ± 0.02 ng/mL to 10.5 ± 1.4 ng/mL (p ≤ 0.01), and a
fivefold increase in IL8 protein from 111.4 ± 15.6 ng/mL to
512.2 ± 28.2 ng/mL (p ≤ 0.01, Figure 1C).
As we aimed to investigate involvement of cPLA2α in
regulating TNF-induced expression of these metabolites, we
further characterized the PLA2G4A gene expression in
synoviocytes. We found the PLA2G4A transcript to be
expressed in untreated cells, and further induced 4.8 ± 1.1-fold
by TNF (p ≤ 0.02, Figure 1D). Collectively, the SW982
synoviocyte model system was found suitable for investigating
potential involvement of cPLA2α in regulating TNF-induced
signaling related to joint destructive processes occurring in the
RA synovium.
AVX002 Efficiently Reduce AA Release and PGE2
Production
The AA metabolite PGE2 is recognized as a potent regulator
of inflammation and the benefits of reducing pathological PGE2
levels are commonly accepted [12]. We aimed to investigate
the effect of the recently described cPLA2α inhibitor AVX002
[25] on cellular AA release and total PGE2 synthesis in the
synoviocyte model system. AVX002 dose-dependently
inhibited the TNF-induced AA release with a mean estimated
IC50 value of 0.9 ± 0.3 μM (Figure 2A). This estimate is based
on 4 independent experiments. AVX002 alone modestly
reduced basal AA release in a dose dependent manner; 5 µM
AVX002 reduced basal AA release by 27%, 2.5 µM and 1.25
µM by 18%, and 0.63 µM by 13%. Furthermore, AVX002 was
found to display long-lasting inhibitory effects evidenced by
reduced TNF-induced AA release to 66 ± 2% of basal level
following 72 hrs of TNF stimulation (p ≤ 0.05) (Figure 2B).
AVX002 inhibitory efficacy was compared to the widely used
commercial cPLA2α inhibitor, ATK [35]. ATK reduced TNF-
induced AA release in a similar fashion as AVX002 (Figure 2A),
however with significantly lower efficacy (p=0.01) as indicated
by the higher mean estimated IC50 value of 2.9 ± 0.8 μM.
Having shown that the inducing effects of TNF on AA release
are normalized toward basal level by cPLA2α inhibitors, we
next aimed to investigate if this finding was also reflected in the
level of PGE2 production. By ELISA analysis, we demonstrated
that production of PGE2 increased fivefold in response to TNF
stimulation compared to basal level, from 52.6 ± 5.7 ng/mL to
265.5 ± 18.7 ng/mL (p ≤ 0.01, Figure 2C). TNF-induced PGE2
production was dose-dependently reduced by AVX002 with a
mean estimated IC50 value of 1.3 ± 0.3 μM. The IC50 estimate
is based on three independent experiments. AVX002 alone
also significantly decreased PGE2 production in unstimulated
cells in a dose-dependent manner by 64% in 0.63 μM, 80% in
2.5 μM and 90% in 10 μM concentrations, compared to
untreated control samples.
Since the metabolization of AA into PGE2 in response to
TNF implies the involvement of the COX pathway, it was of
interest to investigate the expression of the inducible COX2
enzyme. We show that in response to TNF, COX2 mRNA
expression increased 9.0 ± 1.2-fold (p ≤ 0.01), an induction that
was significantly reduced by 50% following AVX002 treatment
(p ≤ 0.03, Figure 1D). Next, we investigated potential
transcriptional regulation of the cPLA2α gene, PLA2G4A. We
found that the fivefold induction by TNF was significantly
reduced by 72% (p ≤ 0.03, Figure 1D), suggesting that cPLA2α
activity may be subject to auto-regulation in response to TNF
stimulation. AVX002 treatment alone did not significantly affect
basal transcription of either gene (results not shown). Hence,
AVX002 served to normalize, not short-circuit gene expression
thereby still allowing basal house-hold activities. Taken
together, the inhibitory effect of AVX002 was evident at several
regulatory levels and at different points in time. cPLA2α and
COX2 enzyme activities are normalized towards basal activity
Cytosolic PLA2 in Rheumatoid Arthritis
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levels as monitored by means of AA release and PGE2
production and secretion. In parallel, COX2 and PLA2G4A
gene expression are also reduced towards, but not below,
basal levels. This suggests that the cPLA2α enzyme has an
important regulatory role at several points in the AA cascade in
synoviocytes.
AVX002 inhibits cPLA2α activity in cell lysates
To validate the inhibitory effect of AVX002 on cPLA2α in our
model system, we investigated the potency of AVX002 to
restrain cPLA2α enzyme activity in cell lysates from untreated
and TNF-stimulated cells. Lysates of TNF-stimulated cells
displayed an 80% increase in activity of cPLA2α compared to
untreated cells as indicated by increased hydrolysis and
release of 14C-AA from phospatidylcholine visualized by TLC
chromatography (Figure 2D). This stimulatory effect is
consistent with the detected induction of AA release by TNF
described above and validates the activation of cPLA2α in
SW982 cells in response to TNF. Detection of cPLA2α activity
in lysates from unstimulated cells indicate a basal enzyme
activity in synoviocytes, as previously described in primary
rheumatoid synoviocytes [36,37], and correlates to the basal
release of AA detected in unstimulated cells (Figure 2A).
Furthermore, AVX002 efficiently inhibited activity of cPLA2α in
lysates from unstimulated cells, as well as TNF-stimulated cells
(Figure 2D). The capacity of AVX002 in inhibiting cPLA2α
enzyme activity in cell lysates agrees with the previously
reported effect on recombinant cPLA2α [25]. Together, these
results support our interpretation that cPLA2α is activated by
TNF in synoviocytes, and that AVX002 directly inhibits cPLA2α
activity resulting in reduced downstream AA release and PGE2
production.
MMP3 expression is regulated by AVX002
To evaluate a potential role for cPLA2α in regulating
destruction of cartilage in RA, we analyzed the effects of
AVX002 on MMP3 expression. Indeed, AVX002 dose-
dependently reduced TNF-induced MMP3 transcription with a
Figure 1.  Inhibition of cPLA2α reduces TNF-induced expression of PLA2G4A, COX2, MMP3 and IL8.  Fibroblast-like
synoviocytes were treated with AVX002 (2 hrs) in indicated concentrations (A, B), 10 µM (C), or 5 µM (D), prior to TNF stimulation
(10 ng/mL, 24 hrs). Total RNA was isolated and transcription of MMP3 (A) and IL8 (B), PLA2G4A and COX2 (D), was analyzed by
real-time PCR as described in the Methods section. Amplification efficiency of all primer pairs were calculated by the LinRegPCR
software and fold-change in gene expression compared to untreated samples was calculated by the REST 2009 software with
GAPDH as reference gene. Supernatants were collected and analyzed by ELISA for MMP3 and IL8 protein (C) as described in the
Method section (note starting point of Y-axis at 0.8). Data shown in all graphs are mean ± SEM (A, B, D) or mean ± SD (C) fold
change compared to untreated samples for one representative of at least three independent experiments performed in duplicates.
Significance is indicated as follows: A) #p ≤ 0.01 vs control; *p, **p ≤ 0.01 vs control and TNF-treated cells. B) #p ≤ 0.01 vs control; *p,
**p, ***p ≤ 0.03 vs control and TNF-treated cells. C) IL8: #p ≤ 0.01 vs control; *p ≤ 0.01 vs control and TNF-treated cells. MMP3: ##p ≤
0.01 vs control, **p ≤ 0.01 vs control and TNF-treated cells. D) COX2: #p ≤ 0.01 vs control; *p ≤ 0.03 vs control and TNF-treated cells.
PLA2G4A: ##p ≤ 0.02 vs control; **p ≤ 0.03 vs TNF-treated cells.
doi: 10.1371/journal.pone.0083555.g001
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maximum inhibition of 69% at 5 μM (p ≤ 0.01, Figure 1A). Basal
MMP3 mRNA expression was not significantly affected by
AVX002 alone (results not shown). Moreover, the TNF-induced
twofold increase in MMP3 protein secretion was significantly
reduced by AVX002 by 68%, from 10.5 ± 1.4 ng/mL to 7.1 ±
0.5 ng/mL (p ≤ 0.01, Figure 1C). These results suggest a role
of cPLA2α in regulating TNF-induced MMP3 expression in
human synoviocytes.
IL8 expression is regulated by AVX002
Next, the effect of AVX002 in regulating expression of the
known neutrophil attractant IL8 was investigated by QPCR and
ELISA immunoassay. AVX002 dose-dependently reduced
TNF-induced up-regulation of IL8 transcription, with a
maximum inhibition of 63% at 5 μM (p ≤ 0.03, Figure 1B). Basal
IL8 gene expression was not affected by AVX002 alone
(results not shown). AVX002 also reduced TNF-induced IL8
protein secretion significantly by 65%, from 512.2 ± 28.2 ng/mL
to 252.7 ± 62.8 ng/mL (p ≤ 0.01, Figure 1C). Accordingly, our
results suggest that in human synoviocytes, TNF-induced IL8
expression may be regulated by cPLA2α.
Discussion
In RA, chronic inflammation and joint destruction is driven by
excessive production of pro-inflammatory cytokines,
chemokines and eicosanoids. In this study, by applying the
chemical cPLA2α inhibitors AVX002 and ATK, we demonstrate
that cPLA2α may be an important effector of TNF in
intracellular signaling directly related to synovitis. Figure 3
summarizes the hypothesized involvement of cPLA2α in
Figure 2.  cPLA2α regulates TNF-induced AA release and PGE2 synthesis.  SW982 synoviocytes were treated with either
AVX002 or ATK (2 hrs) in indicated concentrations (A, C) or 5 µM (B) prior to stimulation with TNF (10 ng/mL) for 24 hrs (A, C) or
indicated times (B). Analysis of released [3H]-AA (A, B) or PGE2 (C) was performed as described in the Methods section. Presented
values are mean ± SD of TNF-induced release compared to untreated control samples in one representative of at least three
independent experiments performed in duplicates (PGE2) or triplicates ([3H]-AA). AA release levels for untreated samples are
indicated by a dash line in (B). Synoviocytes were stimulated with TNF (10 ng/mL) for 6 hours prior to lysis and detection of in vitro
cPLA2α enzyme activity as described in the Methods section (D). Presented values are mean ± SD of in vitro cPLA2α activity (%) in
one representative of at least three independent experiments performed in duplicates. Statistical significance is indicated as follows:
A: #p≤ 0.01 when compared to untreated control values, *p ≤ 0.01 (AVX002) and ¤p ≤ 0.01 (ATK) when compared to TNF-stimulated
control values. B: #p ≤ 0.05 when compared to untreated control values, *p ≤ 0.05 when compared to TNF-stimulated control values.
C: #p ≤ 0.01, ##p ≤ 0.02 when compared to untreated samples, and *p ≤ 0.01 when compared to TNF-stimulated and control values.
D: #p ≤ 0.03 when compared to untreated cell lysates, *p ≤ 0.02 when compared to untreated or TNF-stimulated cell lysates without
inhibitor.
doi: 10.1371/journal.pone.0083555.g002
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regulating synoviocyte expression of key mediators of bone
and cartilage destruction, angiogenesis and recruitment of
immune cells, along with the availability of AA and subsequent
PGE2 production.
Figure 3.  Proposed TNF-induced and cPLA2α dependent
signaling in synoviocytes.  TNF is a powerful inducer of
inflammation and joint destruction in RA. In the SW982
synoviocyte model system, TNF induces activation of the
cPLA2α enzyme to release AA from membranes, presumably
through binding to its receptors TNF receptor 1 and TNF
receptor 2 (TNFR1/TNFR2). AA released by cPLA2α is
metabolized by COX2 to PGE2, a commonly recognized
inducer of inflammation. The TNF-induced AA cascade can be
self-reinforced by transcriptional regulation of COX2 and
PLA2G4A genes. MMP3 and IL8 are central effectors in RA
through cartilage destruction (MMP3), angiogenesis and
attraction of immune cells (IL8). cPLA2α regulates TNF-
induced expression of MMP3 and IL8 on transcriptional and
protein levels. Consequently, cPLA2α functions to coordinate
joint destructive and inflammatory processes in synoviocytes.
doi: 10.1371/journal.pone.0083555.g003
Our results demonstrate that AVX002 efficiently and
persistently reduces AA-release and hence the availability of
substrate for pro-inflammatory eicosanoid production in
synoviocytes (Figure 2). We have previously demonstrated that
AVX002 is a potent inhibitor of recombinant cPLA2α enzyme
activity in vitro [25] and that AVX002 efficiently inhibits PGE2
production in IL-1β stimulated rat mesangial cells. Here, we
provide proof of principle that AVX002 potently inhibits cPLA2α
as we for the first time demonstrate that AVX002 is an inhibitor
of cPLA2α enzyme activity in synoviocytes (Figure 2D).
Analogous effects of cPLA2α inhibition of enzyme activity,
cytokine-induced AA release, PGE2 production and gene
expression has previously been demonstrated with three other
chemical inhibitors resembling AVX002 and ATK in chemical
structure; MAFP, and the trifluoromethyl ketone analogue of
EPA (EPACOCF3) [38–41]. Based on these results and the
herein reported observations on the effects of AVX002 and
ATK in our model system, we postulate that the observed
effects of AVX002 are due to inhibition of cPLA2α enzyme
activity.
The important role of PGE2 in propagating inflammation and
pain is commonly recognized as reflected by the effective
symptom relief of pain and stiffness by NSAID treatment in RA
patients [12,13]. The highly pleiotropic PGE2 exhibits a wide
range of biological actions [42] and is also proposed to be a
central factor in bone and cartilage resorption in arthritis
through regulation of osteoclast activity and expression of
cytokines and MMPs in various model systems [43–45]. The
versatile effects of PGE2 further include promotion of immune
cell influx to inflamed tissue and angiogenesis [46,47]. As
synoviocytes are important promoters of inflammation and joint
destruction in RA, the reduced PGE2 production by AVX002 in
these cells supports a key role for cPLA2α in RA pathogenesis.
Our results further imply that reduced PGE2 synthesis in
response to cPLA2α inhibitors may be self-reinforced through
transcriptional regulation of the COX2 and PLA2G4A genes
(Figure 1D). Transcriptional regulation of COX2 by cPLA2α has
previously been shown in murine model systems [23,48] and
our experiments suggest that this mechanism might be active
also in human synoviocytes. The decrease in PLA2G4A mRNA
in response to cPLA2α inhibition is to our knowledge a novel
finding. It may suggest a feed-back loop from cPLA2α
enzymatic activity through transcriptional regulation of the
PLA2G4A gene in response to TNF in synoviocytes. Feed-back
signaling where enzymatic activity of cPLA2α is required to
regulate its own gene induction is previously reported in lung
fibroblasts in response to IL-1β stimulation [9]. This possible
auto-regulation in response to pro-inflammatory stimuli
presents a potential self-reinforcing impact of inhibiting cPLA2α
enzyme activity.
As degradation of cartilage and bone are major hallmarks of
RA, disruption of these destructive processes represents a
central therapeutic objective. MMP3, with its wide range of
substrate specificity and ability to activate other MMPs, is
essential in RA cartilage degradation [30] and correlate with
disease activity and inflammation markers in RA patients [49].
We identify cPLA2α as a possible regulator of MMP3
expression in human synoviocytes (Figure 1A and C). This
Cytosolic PLA2 in Rheumatoid Arthritis
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correlates with reported findings from murine arthritis [23]
suggesting that cPLA2α is a regulator of cartilage degradation
in RA. Angiogenesis and the continuous influx of immune cells
to the inflamed synovium are important processes driving the
inflammation in RA joints. cPLA2α is proposed to be a regulator
of neutrophil recruitment and inflammation in murine collagen-
induced arthritis [22], and has been found to regulate
expression of the chemotactic and angiogenic factor IL8 in
human lung fibroblasts [50]. We show that cPLA2α enzyme
activity might be involved in regulating IL8 production also in
human synoviocytes (Figure 1B and C), emphasizing the
potential biological relevance of cPLA2α in synovitis.
Given the complexity of TNF signaling networks, focusing on
an intracellular therapeutic target downstream the TNF
receptor may show reduced adverse effects compared to TNF-
blocking therapy as many key host defense mechanisms are
not targeted. Accordingly, a modulation of cPLA2α enzyme
activity by specific cPLA2α inhibitors and subsequently
normalizing downstream signaling may represent an alternative
or supplement to current therapeutic strategies for RA
treatment. Indeed, cPLA2α is expressed in RA synovium [51],
and has been shown to play an important role in inflammation
and in several animal models of arthritis [20–22]. Furthermore,
inhibitors of cPLA2α including ATK and pyrroxyphene
ameliorate various inflammatory conditions including collagen-
induced arthritis in mice [23,52]. Our results expand the
understanding of cPLA2α as a possible regulator of
inflammatory and joint destructive processes in human
synoviocytes through regulation of MMP3, IL8 and PGE2.
Taken together, we demonstrate that cPLA2α may have an
important role in regulating TNF-induced intracellular signaling
in synoviocytes. Hence, our results suggest that cPLA2α may
be involved in both inflammatory, angiogenic and tissue
destructive processes and may hence be a promising
therapeutic target to reduce inflammation and discomfort, pain,
reduced functionality and mobility associated with RA.
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